Aptevo Therapeutics Inc.
http://aptevotherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aptevo Therapeutics Inc.
Stock Watch: Sanofi, Pfizer And The Aftermath Of Acquisitions
Acquisitions usually depress the stock price of the buyer to reflect the dilution and propel the shares of the acquired to reflect the premium. But not always.
Alligator Makes Advances In Pancreatic Cancer
The Swedish biotech is expecting intense discussions with prospective partners for mitazalimab, a couple of years after Janssen returned the rights to the CD40 agonist.
Alligator CEO Provides Snapshot Of Tumor-Directed IO Pipeline
Following a deal, worth potentially $700m plus, signed in 2015 with Johnson & Johnson’s Janssen Biotech, Swedish biotech Alligator Biosciences AB is well placed to drive its clinical pipeline. During the Biotech Showcase, CEO Per Norlén outlined to Scrip the current status of the pipeline and its plans moving forward, which include having five clinical programs in place by the end of 2019.
Pipeline Watch: Phase III Readouts For Eptinezumab, KPI-121 And Omidenepag Isopropyl
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice